par Hofstra, Marije LM;Sauvageot, Nicolas;Albert, Jan;Alexiev, Ivailo;Garcia Colominas, Federico ;Struck, Daniel;Van De Vijver, David A. M. C.;Åsjö, Birgitta;Beshkov, Danail;Coughlan, Suzie;Descamps, Diane;Griskevicius, Algirdas;Hamouda, Osamah;Horban, Andrzej;Van Kasteren, Marjo;Kolupajeva, Tatjana;Kostrikis, Leondios G;Liitsola, Kirsi;Linka, Marek;Mor, Orna;Nielsen, Claus;Otelea, Dan;Paraskevis, Dimitrios;Paredes, Roger;Poljak, Mario;Puchhammer-Stöckl, Elisabeth;Sönnerborg, Anders;Staneková, Danica;Stanojevic, Maja;Van Laethem, Kristel;Zazzi, Maurizio;Zidovec Lepej, Snjezana;Boucher, Charles A B CA;Schmit, Jean-Claude;Wensing, Annemarie M J AM;SPREAD Program,
Référence Clinical infectious diseases, 62, 5, page (655-663)
Publication Publié, 2016-03
Référence Clinical infectious diseases, 62, 5, page (655-663)
Publication Publié, 2016-03
Article révisé par les pairs
Résumé : | Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. |